Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Down 12.4% in November

Alto Neuroscience, Inc. (NYSE:ANRO) was the target of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 4,080,000 shares, a drop of 12.4% from the November 15th total of 4,660,000 shares. Approximately 18.6% of the shares of the company are short sold. Based on an average daily trading volume, of 777,200 shares, the short-interest ratio is presently 5.2 days.

Analyst Ratings Changes

A number of research firms recently commented on ANRO. RODMAN&RENSHAW cut shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Robert W. Baird lowered their target price on Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Wedbush cut Alto Neuroscience from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $29.00 to $4.00 in a research report on Wednesday, October 23rd. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Finally, Rodman & Renshaw cut Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds have recently bought and sold shares of the company. Franklin Resources Inc. grew its position in Alto Neuroscience by 95.3% during the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock worth $13,965,000 after buying an additional 595,673 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Alto Neuroscience by 80.3% during the third quarter. Jennison Associates LLC now owns 832,290 shares of the company’s stock worth $9,521,000 after purchasing an additional 370,612 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Alto Neuroscience by 148.7% in the third quarter. Geode Capital Management LLC now owns 469,988 shares of the company’s stock worth $5,378,000 after purchasing an additional 281,018 shares during the last quarter. State Street Corp increased its position in shares of Alto Neuroscience by 123.7% in the third quarter. State Street Corp now owns 236,857 shares of the company’s stock worth $2,710,000 after purchasing an additional 130,985 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Alto Neuroscience by 182.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 186,968 shares of the company’s stock valued at $2,139,000 after purchasing an additional 120,779 shares in the last quarter.

Alto Neuroscience Stock Performance

Shares of Alto Neuroscience stock traded up $0.04 during trading hours on Tuesday, reaching $3.79. The company had a trading volume of 342,881 shares, compared to its average volume of 370,987. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.10 and a quick ratio of 13.09. Alto Neuroscience has a one year low of $3.58 and a one year high of $24.00. The business has a fifty day simple moving average of $6.21 and a 200 day simple moving average of $9.92.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Tuesday, November 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.05. Research analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.